

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

INNOPHARMA LICENSING, INC., INNOPHARMA LICENSING LLC,  
INNOPHARMA INC., INNOPHARMA LLC,  
MYLAN PHARMACEUTICALS INC., and MYLAN INC.,  
Petitioner,

v.

SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB, INC., and  
BAUSCH & LOMB PHARMA HOLDINGS CORP.,  
Patent Owner.

---

Case IPR2015-00903  
Patent 8,129,431 B2

---

Before FRANCISCO C. PRATS, ERICA A. FRANKLIN, and  
GRACE KARAFFA OBERMANN, *Administrative Patent Judges*.

OBERMANN, *Administrative Patent Judge*.

DECISION  
Instituting *Inter Partes* Review  
37 C.F.R. § 42.108

I. BACKGROUND

On March 19, 2015, Petitioner filed a request for an *inter partes* review of claims 1–22 of U.S. Patent No. 8,129,431 B2 (Ex. 1001, “the ’431 patent”). Paper 2 (“Pet.”). Patent Owner filed a Preliminary Response.

Paper 11 (“Prelim. Resp.”). Also on March 19, 2015, Petitioner filed a Motion for Joinder (Exhibit 0) of this case with *Metrics, Inc. v. Senju Pharmaceutical Co., Ltd.*, IPR2014-01041. We address the Motion for Joinder in an Order filed concurrently herewith.

We have jurisdiction under 35 U.S.C. § 314(a), which provides that an *inter partes* review may be instituted upon a showing of “a reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition.” Petitioner makes that showing with respect to claims 1–22; therefore, we institute review as to those claims.

Our findings of fact and conclusions of law are based on the record developed thus far, prior to Patent Owner’s Response. This is not a final decision as to the patentability of any challenged claim. If a final decision is issued in this case, it will be based on the full record developed during trial.

#### *A. Related Proceedings*

Petitioner identifies eight district court actions involving the ’431 patent, including one that involves Petitioner as a defendant. Pet. 11–12; *see Senju Pharmaceutical Co. v. InnoPharma Licensing, Inc.*, C.A. No. 1:14-CV-06893-JBS-KMW (D.N.J. filed Nov. 3, 2014).

Concurrently herewith, we issue a decision to institute in IPR2015-00902, involving the same parties and directed to U.S. Patent No. 8,669,290 B2 (the ’290 patent). The ’290 patent claims priority to the ’431 patent.

#### *B. The ’431 Patent (Ex. 1001)*

The ’431 patent relates to an aqueous liquid preparation consisting essentially of two components: (1) bromfenac (or its salts and hydrates); and (2) tyloxapol. Ex. 1001, 11:66–12:10. Bromfenac is a non-steroidal anti-inflammatory drug (“NSAID”). *Id.* at 1:24–40. The preparation is

useful for ophthalmic administration, such as an eye drop to treat blepharitis, conjunctivitis, scleritis, and postoperative inflammation. *Id.* at Abstract; 12:5–6. Claim 1 specifies that a quaternary ammonium compound, specifically, benzalkonium chloride (“BAC”), may be included in the liquid preparation. *Id.* at 12:8–9.

An object of the invention is to provide an aqueous liquid preparation of bromfenac that “is stable within a pH range giving no irritation to eyes” when preserved with BAC. *Id.* at 2:15–22. The inventors claim to have discovered that addition of an alkyl aryl polyether alcohol type polymer, such as tyloxapol, provides the sought-after stability, giving no irritation to the eyes. *Id.* at 2:35–49. The inventors acknowledge that tyloxapol “is a non-ionic surfactant.” *Id.* at 4:37–39.

### *C. Illustrative Claim*

Petitioner seeks *inter partes* review of claims 1–22 of the ’431 patent. Independent claim 1, reproduced below, is illustrative of the subject matter.

1. An aqueous liquid preparation consisting essentially of the following two components, wherein the first component is 2-amino-3-(4-bromobenzoyl)-phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, wherein the hydrate is at least one selected from a 1/2 hydrate, 1 hydrate, and 3/2 hydrate and the second component is tyloxapol, wherein said liquid preparation is formulated for ophthalmic administration, and wherein when a quaternary ammonium compound is included in said liquid preparation, the quaternary ammonium compound is benzalkonium chloride.

Ex. 1001, 11:66–12:10.

Claims 3 and 20 specify a tyloxapol concentration that “is from about 0.01 w/v % to about 0.5 w/v %.” Ex. 1001, 12:13–23, 14:13-16. None of the claims of the ’431 patent specify a function for tyloxapol in the preparation. *Id.* at 11:65–14:22 (claims 1–22).

*D. The Applied Prior Art*

Petitioner relies upon the following prior art references:

Ogawa *et al.*, U.S. Patent No. 4,910,225, issued Mar. 20, 1990 (Ex. 1004) (“Ogawa”).

Sallmann *et al.*, U.S. Patent No. 6,107,343, issued Aug. 22, 2000 (Ex. 1009) (“Sallmann”).

Fu, Austl. Patent Application No. AU-B-22042/88, issued Mar. 16, 1989 (Ex. 1011 (“Fu”).

*E. The Asserted Grounds of Unpatentability*

Petitioner asserts that (1) claims 1–5, 7–14, and 18–19 of the ’431 patent are unpatentable under 35 U.S.C. § 103 as obvious over Ogawa and Sallmann; and (2) claims 6, 15–17, and 20–22 are unpatentable under 35 U.S.C. § 103 as obvious over Ogawa, Sallman, and Fu. Pet. 19. Petitioner relies on a declaration of Dr. Paul A. Laskar. Ex. 1003.<sup>1</sup>

---

<sup>1</sup> Dr. Laskar has a Ph.D. in Pharmaceutical Sciences and is the founder of a pharmaceutical development consulting firm focused on development and evaluation of pharmaceuticals, including ophthalmic products. Ex. 1003 ¶¶ 12–13, 17. Dr. Laskar has significant experience in the development and assessment of ophthalmic preparations. Ex. 1003 ¶¶ 14, 16. He appears on this record to have the requisite familiarity with ophthalmic preparations to opine on the views of a hypothetical person of ordinary skill in the art at the time of the invention. *See id.* at ¶¶ 10–17. At this stage of the proceeding, we find his testimony credible and persuasive.

## II. ANALYSIS

### A. Claim Construction

In an *inter partes* review, claim terms in an unexpired patent are interpreted according to their broadest reasonable construction in light of the specification of the patent in which they appear. 37 C.F.R. § 42.100(b); *In re Cuozzo Speed Techs., LLC*, No. 2014–1301, 2015 WL 4097949, at \*5–\*8 (Fed. Cir. July 8, 2015). Claim terms are given their ordinary and customary meaning, as understood by one of ordinary skill in the art in the context of the entire disclosure. *In re Translogic Tech., Inc.*, 504 F.3d 1249, 1257 (Fed. Cir. 2007). If an inventor acts as his or her own lexicographer, the definition must be set forth in the specification with reasonable clarity, deliberateness, and precision. *Renishaw PLC v. Marposs Societa' per Azioni*, 158 F.3d 1243, 1249 (Fed. Cir. 1998). The construction that stays true to the claim language, and most naturally aligns with the inventor's description, is likely the correct interpretation. *Id.* at 1250.

Petitioner addresses the transitional phrase “consisting essentially of” as applied in claims 1–22. Pet. 15–16. Patent Owner responds that none of the terms requires express construction, and takes issue with Petitioner's discussion of that transitional phrase. Prelim. Resp. 14–15. At this stage of the proceeding, we determine that the claim terms are clear on their face, and none is specially defined in the written description of the '431 patent. No claim term requires express construction for the purposes of this decision.

### B. The Applied Prior Art

We next turn to the prior art references applied in the Petition and, in particular, to what those references would have conveyed to an ordinary artisan about the state of the art at the time of the invention of the '431

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.